Breast cancer: With trastuzumab + chemo for HER2+ BC (neoadjuvant, adjuvant, first-line metastatic).
Loading: 840 mg IV. Maintenance: 420 mg IV Q3W.
Injection: 420 mg/14 mL vial
None listed.
Diarrhea (67%), Alopecia (61%), Neutropenia (53%), Nausea (42%), Fatigue (38%), Rash (36%), Peripheral Neuropathy (30%), Decreased Appetite (29%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
No PK interactions with trastuzumab or docetaxel.
Consult the full prescribing information for pregnancy-related considerations.
Refer to prescribing information for lactation guidance.
Pediatric safety and efficacy information is detailed in the full label.
Dose modifications for organ impairment are specified in the complete prescribing information.
Humanized mAb targeting HER2 subdomain II, blocking ligand-dependent heterodimerization and mediating ADCC.
t½: 18 days. Vd: 4.6 L. Steady state by Cycle 7.
Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.
Perjeta has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:
Perjeta (pertuzumab) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.
Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.
Humanized mAb targeting HER2 subdomain II, blocking ligand-dependent heterodimerization and mediating ADCC.
Diarrhea (67%), Alopecia (61%), Neutropenia (53%), Nausea (42%), Fatigue (38%), Rash (36%), Peripheral Neuropathy (30%), Decreased Appetite (29%) Diarrhea 67% Alopecia 61% Neutropenia 53% Nausea 42% Fatigue 38% Rash 36% Peripheral Neuropathy 30% Decreased Appetite 29%